{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:12:25Z","timestamp":1791267145507,"version":"4.1.0"},"reference-count":61,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T00:00:00Z","timestamp":1621900800000},"content-version":"vor","delay-in-days":144,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970801"],"award-info":[{"award-number":["81970801"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2019JJ4001"],"award-info":[{"award-number":["2019JJ4001"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Journal of Ophthalmology"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:p>\n                    <jats:italic>Aim<\/jats:italic>\n                    . Within the clinical setting, some patients have been identified as lacking in response to PGAs. This meta\u2010analysis study aimed to evaluate the responsiveness of latanoprost, travoprost, bimatoprost, and tafluprost in OAG\/OHT patients, latanoprost nonresponders (LNRs), and the IOP\u2010reducing efficacy and safety.\n                    <jats:italic>Methods<\/jats:italic>\n                    . A literature search was conducted on PubMed, Embase, and the Cochrane Controlled Trials Register. The primary clinical endpoint was the number of responders at the end of the study. The secondary clinical endpoint was the IOP reduction at the endpoint from baseline. Safety evaluation included five common adverse events: conjunctival hyperemia, hypertrichosis, ocular burning, ocular itching, and foreign\u2010body sensation.\n                    <jats:italic>Results<\/jats:italic>\n                    . Eleven articles containing ten RCTs were included in this meta\u2010analysis study. The results highlighted that, in the OAG\/OHT population, there was no statistically significant difference in the responsiveness of the four PGAs. Bimatoprost had a better IOP\u2010reducing efficacy than latanoprost. There was no significant difference in the IOP\u2010reducing efficacy of travoprost, latanoprost, and tafluprost. In LNRs, the responsiveness of bimatoprost, travoprost, and latanoprost did not show statistical differences. Bimatoprost reduced IOP with a greater extent than latanoprost and travoprost in LNRs, while there was no significant difference in the IOP\u2010reducing efficacy of travoprost and latanoprost. No serious adverse events occurred with the treatment of the four PGAs. The prevalence of conjunctival hyperemia due to bimatoprost or tafluprost was significantly higher than that of latanoprost. Other adverse events had no significant difference between the four drugs.\n                    <jats:italic>Conclusion<\/jats:italic>\n                    . The existing studies cannot prove that latanoprost, travoprost, bimatoprost, and tafluprost have different responsiveness in OAG\/OHT patients. Switching to bimatoprost or travoprost cannot achieve a significant improvement in responsiveness in LNRs. Bimatoprost has a better IOP\u2010reducing efficacy than latanoprost and travoprost. No serious adverse events occurred during treatment with any medication we studied.\n                  <\/jats:p>","DOI":"10.1155\/2021\/5586719","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T17:50:22Z","timestamp":1621965022000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Analysis of the Responsiveness of Latanoprost, Travoprost, Bimatoprost, and Tafluprost in the Treatment of OAG\/OHT Patients"],"prefix":"10.1155","volume":"2021","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6139-6932","authenticated-orcid":false,"given":"Ziyan","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengdan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1101-0602","authenticated-orcid":false,"given":"Xuanchu","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s118689"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-017-0601-8"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0b013e3182867be3"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2012.662219"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2018.1526279"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108019"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2003.12.014"},{"key":"e_1_2_9_8_2","first-page":"95","article-title":"[Randomized parallel group study of 0.001 5% tafluprost ophthalmic solution in patients with primary open\u2014angle glaucoma or ocular hypertension (comparison with 0.005% latanoprost ophthalmic solution)]","volume":"51","author":"Ge J.","year":"2015","journal-title":"China Journal of Ophthalmol"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.08-3031"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151644"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2003.12.016"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-005-0293-x"},{"key":"e_1_2_9_13_2","first-page":"269","article-title":"[Efficacy of latanoprost monotherapy treatment in primary open-angle glaucoma]","volume":"77","author":"Mart\u00ednez Garc\u00eda A.","year":"2002","journal-title":"Archivos de la Sociedad Espanola de Oftalmologia"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.12.038"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1089\/108076802760116205"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2009.158071"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfo.2019.02.009"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(02)01891-2"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0039-6257(01)00224-7"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0183142"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(02)01827-5"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.2006.106690"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1185\/030079906x148418"},{"key":"e_1_2_9_24_2","first-page":"1595","article-title":"[Phase III confifirmatory study of 0.0015% DE-085 (taflfluprost) ophthalmic solution as compared to 0.005% latanoprost ophthalmic solution in patients with open angle glaucoma or ocular hypertension]","volume":"25","author":"Kuwayama Y.","year":"2008","journal-title":"Atarashii Ganka (Journal of the Eye)"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2009.0066"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S33414"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.09.005"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-4-201302190-00008"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2008.08.010"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s61444"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200320080-00005"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1080\/02713680802669781"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-016-0413-z"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1517\/14656566.2013.748038"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-5155(97)00128-7"},{"key":"e_1_2_9_36_2","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S41562"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.03.025"},{"key":"e_1_2_9_38_2","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-304267"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2008.0028"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1177\/112067210901900110"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-017-0662-5"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121518"},{"key":"e_1_2_9_43_2","first-page":"1068","article-title":"Distribution of myocilin and extracellular matrix components in the juxtacanalicular tissue of human eyes","volume":"43","author":"Ueda J.","year":"2002","journal-title":"Investigative Ophthalmology & Visual Science"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/3027036"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.18240\/ijo.2017.07.13"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/jcmm.15032"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.20028597"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00544.2001"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2014.07.030"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajplung.00247.2016"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1080\/08039488.2018.1468480"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-020-00769-8"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1111\/vop.12843"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/ijg.0000000000000265"},{"key":"e_1_2_9_55_2","article-title":"Preserved versus preservative-free latanoprost for the treatment of glaucoma and ocular hypertension: a post hoc pooled analysis","volume":"2021","author":"Harasymowycz P.","year":"2021","journal-title":"Advances in Therapy"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.2147\/opth.s264984"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.22336\/rjo.2019.38"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1089\/jop.2014.0104"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.04.041"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2008.01381.x"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118785280"}],"container-title":["Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2021\/5586719","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/2021\/5586719","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2021\/5586719","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T03:16:51Z","timestamp":1783653411000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2021\/5586719"}},"subtitle":[],"editor":[{"given":"Enrique","family":"Menc\u00eda-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["10.1155\/2021\/5586719"],"URL":"https:\/\/doi.org\/10.1155\/2021\/5586719","archive":["Portico"],"relation":{},"ISSN":["2090-004X","2090-0058"],"issn-type":[{"value":"2090-004X","type":"print"},{"value":"2090-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"2021-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"5586719"}}